Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment Available to Purchase

2.

Graham

CE

,

Lee

WH

,

Wiggin

HR

, et al.

Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity

.

Blood

.

2023

;

142

(

14

):

1248

-

1252

.

3.

Van Oekelen

O

,

Aleman

A

,

Upadhyaya

B

, et al.

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

.

Nat Med

.

2021

;

27

(

12

):

2099

-

2103

.

4.

Martin

T

,

Usmani

SZ

,

Berdeja

JG

, et al.

Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up

.

J Clin Oncol

.

2023

;

41

(

6

):

1265

-

1274

.

5.

Ellithi

M

,

Elsallab

M

,

Lunning

MA

, et al.

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data

.

Transplant Cell Ther

.

2025

;

31

(

2

):

71.e1

-

71.e14

.

6.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet

.

2021

;

398

(

10297

):

314

-

324

.

7.

Lee

WH

,

Graham

CE

,

Wiggin

HR

, et al.

Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood

.

Cytometry B Clin Cytom

.

2024

;

106

(

3

):

162

-

170

.

8.

Lee

DW

,

Santomasso

BD

,

Locke

FL

, et al.

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

.

Biol Blood Marrow Transplant

.

2019

;

25

(

4

):

625

-

638

.

9.

Kumar

S

,

Paiva

B

,

Anderson

KC

, et al.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

.

Lancet Oncol

.

2016

;

17

(

8

):

e328

-

e346

.